10HO image
Deposition Date 2026-01-20
Release Date 2026-09-09
Last Version Date 2026-09-09
Entry Detail
PDB ID:
10HO
Keywords:
Title:
Crystal structure of alkaline nuclease from Herpes simplex virus-1
Biological Source:
Source Organism(s):
Expression System(s):
Method Details:
Experimental Method:
Resolution:
2.46 Å
R-Value Free:
0.23
R-Value Work:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Deoxyribonuclease
Chain IDs:A
Chain Length:534
Number of Molecules:1
Biological Source:Human alphaherpesvirus 1
Primary Citation
Viral Nuclease Inhibitors: Small molecule disruptors of the UL12 alkaline nuclease display broad anti-herpes virus activity.
Plos Pathog. 22 e1014531 e1014531 (2026)
PMID: 42607086 DOI: 10.1371/journal.ppat.1014531

Abstact

Herpes simplex virus 1 (HSV-1) UL12 encodes a highly conserved 5' --> 3' alkaline exonuclease that is essential for the production of infectious virus. Together with the viral single-stranded DNA-binding/annealing protein ICP8, UL12 functions as a two-component recombinase that mediates recombination-dependent viral DNA replication. Here, we present the crystal structure of the catalytic domain of the HSV alkaline nuclease (UL12), which provides the first view of an alpha-herpesvirus alkaline nuclease. Using this structure, we optimized a series of small-molecule viral nuclease inhibitors (VNIs) that target the UL12 active site and potently inhibit UL12 exonuclease activity in vitro. We have thus established a robust platform for structure-based docking, SAR analysis and rational inhibitor design. Because UL12 orthologs are conserved across all human herpesviruses, we examined the activity of these compounds against the beta- and gamma-herpesvirus alkaline nucleases UL98 and SOX and found that they inhibit all three enzymes. The VNIs also exhibit antiviral activity against HSV-1 and HCMV in cell culture. EC50 and IC50 values were in the nanomolar to low micromolar range. Together, these findings establish herpesvirus alkaline nucleases as conserved, druggable antiviral targets and provide a foundation for the development of broad-spectrum anti-herpesvirus therapeutics, either as standalone agents or in combination with existing nucleoside analogs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback